Researchers from Purdue University in the US have discovered that stimulating the production of a special enzyme, DDX5, in the human liver increases the effectiveness of anti-cancer therapy directed at the organ. results published Cell Death and Disease.
One of the most common anticancer drugs used to treat liver cancer is Sorafenib. Currently, its use can extend the life of patients with the disease by two to three months, but it does not cure cancer. Scientists have searched for ways to make this drug more effective.
They found that increasing the level in the body of DDX5, a special enzyme synthesized by the liver, increased the antitumor properties of Sorafenib. Scientists have already conducted an experiment involving laboratory mice. Rodents were divided into two groups. Rodent liver malignancies caused by implantation of engineered cancer cells were treated with Sorafenib with or without the antibiotic Doxycycline. Doxycycline has been used to stimulate DDX5 production.
The results showed that the simultaneous use of Doxycycline and Sorafenib contributed to more significant regression of tumors. The authors of the study hope that their discovery will allow the development of new methods to treat liver cancer based on stimulation of the synthesis of the DDX5 enzyme. This will increase the survival rate of patients with this disease.
Previous scientists I learnedIt turns out that carrot juice reduces inflammation in the body and protects against cancer.